Anti-amyloid Alzheimer’s Drugs Show No Clinically Meaningful Effect, Major Review Finds Recent analysis of anti-amyloid monoclonal antibody treatments for Alzheimer’s disease reveals these medications provide little to no meaningful benefit …
Tag:
Placebo
-
-
Exercise and Ibuprofen May Help Reduce Cognitive Impairment During Chemotherapy A new Phase II clinical trial has found that both exercise and low-dose ibuprofen can help lessen cognitive problems in …
-
Weight Loss Drug Semaglutide Fails to Leisurely Alzheimer’s Progression Despite initial optimism stemming from observational studies and biomarker changes, recent Phase 3 clinical trials published in The Lancet have demonstrated …
-
Gut Microbiome May Predict Response to GLP-1 Weight Loss Medications New research highlights the growing understanding of how the gut microbiome influences the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 …
-
Chronic Back Pain Amplifies Sounds, Brain Research Reveals New Treatment Hope People with chronic back pain don’t just experience physical discomfort – they may also perceive everyday sounds as harsher …
-
Technology
Dapiglutide Trial: Dual Gut Hormone Agonist Shows Promise But Fails to Beat Placebo for Obesity
Dapiglutide: Novel GLP-1/GLP-2 Agonist Shows Promise in Early Obesity Trials A new drug, dapiglutide, combining GLP-1 and GLP-2 receptor activation, is being investigated as a potential treatment for obesity. Early …
-
DMT Shows Promise in Rapidly Reducing Depressive Symptoms A recent clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation and the need for …
-
Probiotic Form Impacts Brain Health: New Research on Gut-Brain Axis How you consume probiotics – whether encapsulated or in powder form – can significantly influence their impact on brain health, …
-
New clinical trial evidence suggests targeting both obesity and sleep-disordered breathing together may reshape cardiometabolic risk management in obstructive sleep apnea. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes …
-
Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who received a …
Newer Posts